Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-DASATINIB | 70MG | TABLET | Resolved | 2022-07-19 | 2022-08-12 | 164882 |
| APO-DASATINIB | 50MG | TABLET | Resolved | 2022-10-21 | 2022-12-17 | 172360 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2022-11-20 | 2022-12-17 | 175315 |
| APO-DASATINIB | 20MG | TABLET | Resolved | 2022-12-05 | 2023-03-16 | 177126 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2020-10-14 | 2020-11-02 | 126277 |
| APO-DASATINIB | 50MG | TABLET | Resolved | 2021-01-08 | 2021-03-17 | 131145 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2021-01-29 | 2021-03-25 | 132715 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2021-02-19 | 2021-03-04 | 134430 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2024-04-19 | 2024-06-21 | 225776 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2017-08-24 | 2017-09-22 | 20281 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2018-01-18 | 2018-02-12 | 36432 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2024-09-27 | 2024-12-20 | 238844 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2020-08-06 | 2020-11-28 | 121891 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2020-04-13 | 2020-05-22 | 111901 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2020-05-08 | 2020-05-22 | 114285 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2020-06-04 | 2020-07-28 | 116533 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2018-03-13 | 2018-07-03 | 42717 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2023-09-07 | 2023-09-15 | 203819 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Actual shortage | 2025-04-10 | 2025-05-01 | 254838 |
| APO-DEFERASIROX (TYPE J) | 180MG | TABLET | Resolved | 2025-02-13 | 2025-02-21 | 250319 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |